393 related articles for article (PubMed ID: 10566724)
1. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
2. Shingles during the course of treatment with 6-mercaptopurine for inflammatory bowel disease.
Korelitz BI; Fuller SR; Warman JI; Goldberg MD
Am J Gastroenterol; 1999 Feb; 94(2):424-6. PubMed ID: 10022640
[TBL] [Abstract][Full Text] [Related]
3. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Kim PS; Zlatanic J; Korelitz BI; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
Markowitz J; Grancher K; Mandel F; Daum F
Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
[TBL] [Abstract][Full Text] [Related]
5. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database.
Vind I; Riis L; Jess T; Knudsen E; Pedersen N; Elkjaer M; Bak Andersen I; Wewer V; Nørregaard P; Moesgaard F; Bendtsen F; Munkholm P;
Am J Gastroenterol; 2006 Jun; 101(6):1274-82. PubMed ID: 16771949
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory bowel disease in Iran: a review of 457 cases.
Aghazadeh R; Zali MR; Bahari A; Amin K; Ghahghaie F; Firouzi F
J Gastroenterol Hepatol; 2005 Nov; 20(11):1691-5. PubMed ID: 16246187
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up.
Baumgart DC; Pintoffl JP; Sturm A; Wiedenmann B; Dignass AU
Am J Gastroenterol; 2006 May; 101(5):1048-56. PubMed ID: 16573777
[TBL] [Abstract][Full Text] [Related]
8. Are patients with inflammatory bowel disease receiving optimal care?
Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
[TBL] [Abstract][Full Text] [Related]
9. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
10. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease.
Disanti W; Rajapakse RO; Korelitz BI; Panagopoulos G; Bratcher J
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1025-9. PubMed ID: 16765651
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine neoplasms arising in inflammatory bowel disease: a report of 14 cases.
Sigel JE; Goldblum JR
Mod Pathol; 1998 Jun; 11(6):537-42. PubMed ID: 9647591
[TBL] [Abstract][Full Text] [Related]
12. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.
Hibi T; Iwao Y; Yajima T; Inoue N; Ueno Y; Takaishi H; Watanabe M; Ishii H
J Gastroenterol; 1995 Nov; 30 Suppl 8():121-3. PubMed ID: 8563872
[TBL] [Abstract][Full Text] [Related]
14. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
[TBL] [Abstract][Full Text] [Related]
15. Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study.
Katsanos KH; Vermeire S; Christodoulou DK; Riis L; Wolters F; Odes S; Freitas J; Hoie O; Beltrami M; Fornaciari G; Clofent J; Bodini P; Vatn M; Nunes PB; Moum B; Munkholm P; Limonard C; Stockbrugger R; Rutgeerts P; Tsianos EV;
Digestion; 2007; 75(2-3):113-21. PubMed ID: 17598963
[TBL] [Abstract][Full Text] [Related]
16. [Epidemiology of inflammatory bowel diseases in Veszprém county of Western Hungary between 1977 and 2001].
Lakatos L; Mester G; Erdélyi Z; Balogh M; Szipócs I; Kamarás G; Lakatos PL
Orv Hetil; 2003 Sep; 144(37):1819-27. PubMed ID: 14596020
[TBL] [Abstract][Full Text] [Related]
17. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
[TBL] [Abstract][Full Text] [Related]
18. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
19. Cancer in inflammatory bowel disease.
Greenstein AJ
Mt Sinai J Med; 2000 May; 67(3):227-40. PubMed ID: 10828908
[TBL] [Abstract][Full Text] [Related]
20. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
